Efficacy of Tenofovir Disoproxil Fumarate to Prevent Vertical Transmission in Mothers with Lamivudine-Resistant HBV

Abstract

Background

In China, women with chronic HBV infection and who are of childbearing age receive lamivudine at an early age. Thus, viral resistance becomes a challenge for intervention to prevent mother-to-infant transmission. We prospectively assessed the efficacy of tenofovir in pregnant women with lamivudine-resistant HBV.

Methods

Chronic HBV-infected mothers resistant to lamivudine were enrolled. Tenofovir was administrated at gestation weeks 24 or 28. Virological and biochemical parameters were assessed. All infants received combined immunoprophylaxis and were followed for 1 year.

Results

Of the 48 mothers enrolled, 21 started tenofovir therapy at gestation week 24 and 27 started at week 28. Tenofovir resulted in an HBV DNA decline of 5.23 ±1.68 log₁₀ IU/ml at delivery. The group starting therapy at week 24 exhibited a more rapid viral inhibition (P<0.001) and more significant HBV DNA load decline (5.89 ±1.66 versus 4.72 ±1.55; P=0.019) than the group starting at week 28. At delivery, all mothers had a viral titre <10⁶ IU/ml, 76.2% from the week 24 starting group displayed virus <10⁴ IU/ml, and 52.4% showed undetectable virus at delivery, much higher than the week 28 starting group (29.6%), although there was no statistically significant difference in viral levels at delivery between the two groups. Congenital abnormalities and neonatal growth were comparable to the normal population. No case of perinatal transmission was diagnosed.

Conclusions

This investigation clarifies the efficacy of tenofovir for reducing vertical transmission of HBV in mothers with lamivudine-resistant HBV and demonstrates that tenofovir is well-tolerated in the second and third trimesters.

References

Stevens

C.E.

, Beasley

R.P.

, Tsui

, Lee

W.C.

Vertical transmission of hepatitis B antigen in Taiwan.

N Engl J Med 1975; 292: 771–774.

Lee

A.K.

, Ip

H.M.

, Wong

V.C.

Mechanisms of maternal-fetal transmission of hepatitis B virus.

J Infect Dis 1978; 138: 668–671.

Petersen

HBV treatment and pregnancy.

J Hepatol 2011; 55: 1171–1173.

Guo

, Shi

X.H.

, Feng

Y.L.

Risk factors of HBV intrauterine transmission among HBsAg-positive pregnant women.

J Viral Hepat 2013; 20: 317–321.

X.M.

, Shi

M.F.

, Yang

Y.B.

Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection.

World J Gastroenterol 2004; 10: 3215–3217.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B: update 2009.

Hepatology 2009; 50: 661–662.

Liaw

Y.F.

, Leung

, Kao

J.H.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.

Hepatol Int 2008; 2: 263–283.

European Association For The Study Of The Liver.

EASL clinical practice guidelines: management of chronic hepatitis B virus infection.

J Hepatol 2012; 57: 167–185.

Malespin

, Wong

, Siqueira

Barriers to treatment of hepatitis B in an urban Chinatown community.

J Clin Gastroenterol 2012; 46: e66–e70.

10.

Lok

A.S.

, Lai

C.L.

, Leung

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

Gastroenterology 2003; 125: 1714–1722.

11.

Ayres

, Yuen

, Jackson

K.M.

Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations.

J Viral Hepat 2014; 21: 809–817.

12.

Corsa

A.C.

, Liu

, Flaherty

J.F.

No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.

Clin Gastroenterol Hepatol 2014; 12: 2106–2112.e1.

13.

van Bömmel

, de Man

R.A.

, Wedemeyer

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.

Hepatology 2010; 51: 73–80.

14.

Delaney

W.E.

, Ray

A.S.

, Yang

H.L.

Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.

Antimicrob Agents Chemother 2006; 50: 2471–2477.

15.

Brunelle

M.N.

, Lucifora

, Neyts

In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.

Antimicrob Agents Chemother 2007; 51: 2240–2243.

16.

Y.H.

, Liu

, Yi

, Cao

Y.J.

, Cai

H.D.

Tenofovir rescue therapy in pregnant females with chronic hepatitis B.

World J Gastroenterol 2015; 21: 2504–2509.

17.

Chen

, Wang

, Feng

Dynamic changes of HBV markers and HBV DNA load in infants born to HBsAg(+) mothers: can positivity of HBsAg or HBV DNA at birth be an indicator for HBV infection of infants?

BMC Infect Dis 2013; 13: 524.

18.

Sun

K.X.

, Li

, Zhu

F.C.

A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women.

Vaccine 2012; 30: 5335–5340.

19.

Han

G.R.

, Cao

M.K.

, Zhao

A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection.

J Hepatol 2011; 55: 1215–1221.

20.

, Zhu

Z.H.

, Zhang

D.Y.

[A national survey on growth of children under 7 years of age in nine cities of China, 2005].

Zhonghua Er Ke Za Zhi 2007; 45: 609–614. Chinese.

21.

Tsai

P.J.

, Chang

, Yamada

, Tsai

, Bartholomew

M.L.

Use of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women.

Dig Dis Sci 2014; 59: 2797–2803.

22.

Wang

, Kourtis

A.P.

, Ellington

, Legardy-Williams

, Bulterys

Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.

Clin Infect Dis 2013; 57: 1773–1781.

23.

Greenup

A.J.

, Tan

P.K.

, Nguyen

Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.

J Hepatol 2014; 61: 502–507.

24.

Celen

M.K.

, Mert

, Ay

Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection.

World J Gastroenterol 2013; 19: 9377–9382.

25.

Pan

C.Q.

, Mi

L.J.

, Bunchorntavakul

Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series.

Dig Dis Sci 2012; 57: 2423–2429.

26.

Dienstag

J.L.

, Perrillo

R.P.

, Schiff

E.R.

, Bartholomew

, Vicary

, Rubin

A preliminary trial of lamivudine for chronic hepatitis-B infection.

N Engl J Med 1995; 333: 1657–1661.

27.

Suzuki

, Tsubota

, Arase

Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.

Intervirology 2003; 46: 182–189.

28.

Kim

H.J.

, Park

J.H.

, Park

D.I.

The influence of YMDD mutation patterns on clinical outcomes in patients with adefovir add-on lamivudine combination treatment.

Liver Int 2012; 32: 303–310.

29.

Marcellin

, Heathcote

E.J.

, Buti

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

N Engl J Med 2008; 359: 2442–2455.

30.

European Association For The Study Of The Liver.

EASL clinical practice guidelines. management of chronic hepatitis B.

J Hepatol 2009; 50: 227–242.

31.

Wen

W.H.

, Chang

M.H.

, Zhao

L.L.

Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention.

J Hepatol 2013; 59: 24–30.

32.

Pan

C.Q.

, Han

G.R.

, Jiang

H.X.

Telbivudine Prevents Vertical Transmission From HBeAg-Positive Women With Chronic Hepatitis B.

Clin Gastroenterol Hepatol 2012; 10: 520–526.

33.

Wiseman

, Fraser

M.A.

, Holden

Perinatal transmission of hepatitis B virus: an Australian experience.

Med J Aust 2009; 190: 489–492.